CureVac Past Earnings Performance

Past criteria checks 0/6

CureVac's earnings have been declining at an average annual rate of -21.3%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 20.5% per year.

Key information

-21.3%

Earnings growth rate

75.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate20.5%
Return on equity-50.2%
Net Margin-705.0%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26
What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29
Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

CureVac BV reports Q2 results

Aug 18

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

Jul 05

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

May 29
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

May 02
Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

Oct 28
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac: Wait For Concrete News Before Investing

Sep 01

CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy

Jun 16

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02
CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?

Mar 03
How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?

CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma

Feb 04

Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)

Jan 27
Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)

CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates

Jan 11

CureVac, Bayer agree to COVID-19 vaccine alliance - report

Jan 07

Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?

Dec 23
Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?

Curevac advances COVID-19 vaccine candidate to Phase 3 trial

Dec 21

CureVac commences global mid-stage trial for COVID-19 vaccine candidate

Dec 14

CureVac rises 7% on manufacturing deal for COVID-19 vaccine candidate

Dec 09

CureVac BV reports Q3 results

Nov 30

Revenue & Expenses Breakdown
Beta

How CureVac makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:CVAC Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2343-30295110
30 Jun 2338-30110395
31 Mar 2350-29110676
31 Dec 2267-24910763
30 Sep 2297-122100566
30 Jun 22115-219103602
31 Mar 22117-313105722
31 Dec 21103-412102816
30 Sep 2168-468102322
30 Jun 2144-36181308
31 Mar 2156-21964208
31 Dec 2049-12954114
30 Sep 2050-1075689
31 Mar 2017-1025643
31 Dec 1917-1005143
31 Dec 1813-712642

Quality Earnings: CVAC is currently unprofitable.

Growing Profit Margin: CVAC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CVAC is unprofitable, and losses have increased over the past 5 years at a rate of 21.3% per year.

Accelerating Growth: Unable to compare CVAC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CVAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: CVAC has a negative Return on Equity (-50.19%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.